Women living with (what was until very recently known as) PCOS have universally described an experience of dismissal by the modern healthcare system. They talked about relentless hunger, stubborn weight gain, insulin resistance, fatigue, and a relationship with food that felt fundamentally different from what others around them seemed to empathize with. Too often, they were told the answer rested on willpower, or their provider’s perceived lack of it.
That disconnect is one reason experts recently proposed renaming the condition Polyendocrine Metabolic Ovarian Syndrome, or PMOS. The new name reflects a growing recognition that this isn’t simply an ovarian condition, but a complex metabolic and endocrine disorder that affects far more than reproductive health, placing greater emphasis on the hormonal and metabolic dysfunction many patients have long felt was being overlooked.
Against that backdrop, researchers from Ro presented new data at ENDO 2026 examining food noise, now defined scientifically as persistent, intrusive thoughts about food and one of the defining conversations of the GLP-1 era. Using data from more than 75,000 women seeking treatment for overweight or obesity, including more than 10,000 with PMOS, researchers set out to determine whether the condition itself was associated with higher levels of food noise.
The findings were more nuanced than many might have anticipated. After adjusting for demographic, hormonal, behavioral, psychosocial, and metabolic factors, PMOS itself was not independently associated with food noise. At first glance, that might seem surprising given how many women with PMOS describe struggles with appetite, cravings, and food-related thoughts.
A closer look at the data tells a more interesting story. Researchers found that food noise was significantly associated with anxiety, weight stigma, sleep quality, diet quality, oral contraceptive use, BMI, and a history of prediabetes or diabetes. In other words, while PMOS itself wasn’t independently linked to food noise, many of the conditions and experiences that frequently accompany it were.
That distinction matters. For many women in the On The Pen community, the question has never been whether PMOS affects their relationship with food — they already know it does. The question is whether researchers can identify which biological, metabolic, and psychological factors are driving that experience. This study suggests the answer may be more complex than a single diagnosis, but it also suggests patients may have been pointing researchers in the right direction all along.
In many ways, the most important takeaway isn’t what the study found, but what it represents. For years, women with PMOS have described experiences that sound remarkably similar to what many GLP-1 users now call food noise. The fact that researchers are now trying to measure and understand those experiences reflects a broader shift in obesity medicine, one that increasingly takes patient experience seriously rather than dismissing it as a matter of willpower.
That shift is occurring alongside the rise of GLP-1 therapies, which have fundamentally changed the conversation around appetite regulation. Over the years, countless women in the On The Pen community have shared stories about finally feeling relief after starting treatment, not just quieter hunger, but reduced inflammation and fewer of the comorbidities that often accompany PMOS. For some, that reduction in food noise brought an uncomfortable realization: the battle they’d spent years blaming on themselves may have been rooted in biology all along.
Ro also presented new data at ADA 2026 showing that patients with obesity and obstructive sleep apnea reported meaningful improvements after treatment with tirzepatide. Nearly 87% reported improvement in at least one sleep-related outcome, while more than 72% reported improved energy levels. Roughly 60% reported improvements in daytime sleepiness, sleep quality, or snoring, reinforcing what many patients have reported anecdotally since GLP-1 therapies entered the obesity treatment landscape.
Another analysis found that patients who switched between GLP-1 therapies reported side effects more frequently than those who stayed on a single medication. About two-thirds of treatment switchers reported at least one adverse event, compared with just over half of patients who remained on continuous therapy. Gastrointestinal side effects, including nausea, constipation, and diarrhea, were particularly common among those who changed medications.
Taken together, these studies point to an important evolution in obesity research that we keep coming back to at On The Pen: the focus is shifting beyond pounds lost to outcomes that matter in everyday life, including appetite, sleep, energy, quality of life, and treatment tolerability. Those outcomes may not fit neatly on a scale, or into a tidy package for Wall Street, but they often determine whether patients feel healthier, happier, and more in control of their lives.
For women living with PMOS, that shift is long overdue. The science is still evolving, and many questions remain unanswered. But after years of being told their struggles were simply a matter of discipline, researchers are finally investigating the possibility that patients understood something important all along.
Sometimes progress begins with a new treatment. Sometimes it begins with researchers and organizations willing to look at a problem differently. It begins when science starts asking the questions patients have been asking for years.
